Company Overview and News
Data review of Frontier’s projects has been initiated by a major gold miner in mid-November and is ongoing.
The company drilled four diamond core holes on the Central Lower Horizon that targeted flat lying and moderate gold mineralised zones. All core samples are still on-site at this stage awaiting batch finalisation and shipment. The drill rig shifted to “Pad 2” in East Creek, to target a 3 metre wide zone that graded 45.2 g/t gold in previous jackhammer channel samples. The geological log from the first hole on Pad 2 indicates significant visible mineralisation and veining in the core from the surface to 25.
Frontier Resources Ltd (ASX:FNT) has completed the review of historical geological and airborne geophysical data for the Baia and Cecelia Projects in Muller Range, Papua New Guinea. The projects were discovered as anomalous copper and gold in stream sediment and were held most recently by Barrick Gold. The primary targets for Frontier are shallow buried porphyry copper-molybdenum-gold mineralisation plus higher grade skarns and epithermal gold.
Frontier Resources (AIM:FRI), is pleased to announce it has conditionally agreed to acquire Concepta Diagnostics Limited ("Concepta"), a pioneering UK healthcare company established in 2013, that has developed proprietary products and a platform, which targets the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility. SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Securities as Broker.
The Board of Frontier (AIM:FRI), is pleased to provide shareholders with the final results for the year ended 31 December 2015. Chairman's Statement 2015 was without doubt a very challenging year for the Company. Volatility in global financial markets and the steep decline in oil prices made it exceptionally difficult for the Company to progress its farm-out discussions in respect of its then owned portfolio of oil exploration assets in Africa and the Middle East, and particularly Oman or secure new funding for its oil exploration activities.
Frontier Resources Ltd’s (ASX:FNT) share price has increased recently as the company edges closer to mobilising a drilling team exploring for gold at the Swit Kia Prospect in Bulago, Papua New Guinea. A diamond core drilling program will commence this week on the eastern strike extensions of the Upper Zone within the Swit Kia Prospect. The initial target to be drilled is a 2 metres wide interval that graded a whopping 195 g/t gold from 77-degree south dip in jackhammer trench sampling, followed by the Lower Zone that graded 3 metres at 45.
20h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
20h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...